These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 31014399)

  • 1. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
    Butterfield LH; Vujanovic L; Santos PM; Maurer DM; Gambotto A; Lohr J; Li C; Waldman J; Chandran U; Lin Y; Lin H; Tawbi HA; Tarhini AA; Kirkwood JM
    J Immunother Cancer; 2019 Apr; 7(1):113. PubMed ID: 31014399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulated NF-κB-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma.
    Maurer DM; Adamik J; Santos PM; Shi J; Shurin MR; Kirkwood JM; Storkus WJ; Butterfield LH
    Cancer Immunol Res; 2020 Dec; 8(12):1554-1567. PubMed ID: 33051240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma.
    De Keersmaecker B; Claerhout S; Carrasco J; Bar I; Corthals J; Wilgenhof S; Neyns B; Thielemans K
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.
    Trepiakas R; Berntsen A; Hadrup SR; Bjørn J; Geertsen PF; Straten PT; Andersen MH; Pedersen AE; Soleimani A; Lorentzen T; Johansen JS; Svane IM
    Cytotherapy; 2010 Oct; 12(6):721-34. PubMed ID: 20429791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
    Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.
    Wilgenhof S; Van Nuffel AM; Corthals J; Heirman C; Tuyaerts S; Benteyn D; De Coninck A; Van Riet I; Verfaillie G; Vandeloo J; Bonehill A; Thielemans K; Neyns B
    J Immunother; 2011 Jun; 34(5):448-56. PubMed ID: 21577140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro.
    Vujanovic L; Ranieri E; Gambotto A; Olson WC; Kirkwood JM; Storkus WJ
    Cancer Gene Ther; 2006 Aug; 13(8):798-805. PubMed ID: 16645618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
    Butterfield LH; Comin-Anduix B; Vujanovic L; Lee Y; Dissette VB; Yang JQ; Vu HT; Seja E; Oseguera DK; Potter DM; Glaspy JA; Economou JS; Ribas A
    J Immunother; 2008 Apr; 31(3):294-309. PubMed ID: 18317358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
    Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
    Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
    Cebon JS; Gore M; Thompson JF; Davis ID; McArthur GA; Walpole E; Smithers M; Cerundolo V; Dunbar PR; MacGregor D; Fisher C; Millward M; Nathan P; Findlay MPN; Hersey P; Evans TRJ; Ottensmeier CH; Marsden J; Dalgleish AG; Corrie PG; Maria M; Brimble M; Williams G; Winkler S; Jackson HM; Endo-Munoz L; Tutuka CSA; Venhaus R; Old LJ; Haack D; Maraskovsky E; Behren A; Chen W
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
    Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
    Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity.
    Carreno BM; Becker-Hapak M; Huang A; Chan M; Alyasiry A; Lie WR; Aft RL; Cornelius LA; Trinkaus KM; Linette GP
    J Clin Invest; 2013 Aug; 123(8):3383-94. PubMed ID: 23867552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.
    Legat A; Maby-El Hajjami H; Baumgaertner P; Cagnon L; Abed Maillard S; Geldhof C; Iancu EM; Lebon L; Guillaume P; Dojcinovic D; Michielin O; Romano E; Berthod G; Rimoldi D; Triebel F; Luescher I; Rufer N; Speiser DE
    Clin Cancer Res; 2016 Mar; 22(6):1330-40. PubMed ID: 26500235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma.
    Palucka AK; Dhodapkar MV; Paczesny S; Burkeholder S; Wittkowski KM; Steinman RM; Fay J; Banchereau J
    J Immunother; 2003; 26(5):432-9. PubMed ID: 12973032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
    Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
    Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.
    Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Ross MI; Haas NB; von Mehren M; Grosh WW
    J Clin Oncol; 2011 Jul; 29(21):2924-32. PubMed ID: 21690475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients.
    Tuettenberg A; Becker C; Huter E; Knop J; Enk AH; Jonuleit H
    Int J Cancer; 2006 May; 118(10):2617-27. PubMed ID: 16353138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
    Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.